Welcome to our dedicated page for Avadel Pharmaceu SEC filings (Ticker: AVDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avadel Pharmaceuticals plc (Nasdaq: AVDL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. Avadel is an Ireland-incorporated biopharmaceutical company focused on sleep-related disorders, and its filings provide detailed information on its commercial product LUMRYZ, clinical programs, licensing arrangements and corporate transactions.
Investors can review Avadel’s Form 10-K annual reports and Form 10-Q quarterly reports for narrative and quantitative discussions of LUMRYZ net product revenue, patient uptake, research and development spending, and risk factors related to narcolepsy, idiopathic hypersomnia and broader business operations. Current reports on Form 8-K highlight material events such as the Transaction Agreement and subsequent amendment with Alkermes plc, the proposed court-sanctioned scheme of arrangement under Irish law, settlement and license agreements with Jazz Pharmaceuticals, and the exclusive global license for valiloxybate from XWPharma.
These filings also document key clinical and regulatory milestones, including the FDA approvals that made LUMRYZ the first and only once-at-bedtime oxybate for extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy, Orphan Drug Exclusivity grants, and the design and status of Phase 3 studies such as REST-ON and REVITALYZ. Transaction-related disclosures describe the structure, consideration and conditions of the proposed acquisition by Alkermes and the evaluation of alternative proposals under the Irish Takeover Rules.
On Stock Titan, each new AVDL filing from EDGAR is surfaced in real time and paired with AI-powered summaries that explain the main points in clear language. Users can quickly see which filings involve LUMRYZ clinical data, royalty and license agreements, or the Alkermes acquisition terms, and can drill down into the full text for deeper analysis. Insider ownership and compensation details, when disclosed in proxy materials and related documents, are also accessible through the SEC filings stream, helping investors build a comprehensive view of governance and incentives at Avadel.
Avadel Pharmaceuticals director Peter J. Thornton reported the cash-out of his equity holdings in connection with Alkermes plc’s acquisition of Avadel. On February 12, 2026, 115,060 Ordinary Shares were disposed of at $21.00 per share in cash, with each share also receiving a contingent value right for a potential additional $1.50 in cash per share upon milestone achievement.
On the same date, multiple stock option awards covering Ordinary Shares, with exercise prices ranging from $2.03 to $16.32 and expirations from 2029 to 2035, were canceled. Each option was exchanged for cash equal to the in-the-money value based on the $21.00 cash consideration per underlying share, plus one contingent value right for each underlying share. Following these transactions, Thornton reported holding no Ordinary Shares or stock options.
Avadel Pharmaceuticals general counsel Jerad G. Seurer reported the automatic disposition of his equity in connection with Alkermes plc’s acquisition of Avadel under a scheme of arrangement.
On February 12, 2026, each outstanding ordinary share was converted into $21.00 in cash plus a non-transferable contingent value right for a potential additional $1.50 per share, subject to milestone achievement. His 23,496 ordinary shares, including previously restricted shares, were treated on the same terms.
On the same date, multiple stock option awards with exercise prices ranging from $4.69 to $13.57 per share were canceled. Each option was exchanged for cash equal to the in-the-money value based on the $21.00 cash consideration, plus one contingent value right for each underlying share.
Avadel Pharmaceuticals director Linda Palczuk reported the automatic disposition of her holdings in connection with Avadel’s acquisition by Alkermes plc under an Irish scheme of arrangement. She disposed of 78,905 Ordinary Shares at $21.00 per share, with each share also receiving a non-transferable contingent value right for a potential additional $1.50 per share.
The filing also shows the disposition of multiple Avadel stock options held by a revocable trust for which she is trustee. At the effective time on February 12, 2026, each outstanding option was cancelled and exchanged for cash equal to the spread over $21.00 per underlying share plus one contingent value right per underlying share, regardless of vesting.
Avadel Pharmaceuticals CFO Thomas S. McHugh reported the disposition of his ordinary shares and stock options in connection with Alkermes plc’s acquisition of the company. At the effective time of the scheme of arrangement, each outstanding ordinary share was converted into $21.00 in cash plus a non-transferable contingent value right for a potential additional $1.50 per share, contingent on specified milestones.
The filing shows 100,400 ordinary shares disposed of at $21.00 per share, leaving no ordinary shares held directly afterward. Multiple stock options covering various numbers of ordinary shares, with exercise prices ranging from $3.45 to $13.57, were canceled and exchanged for cash based on the spread to the $21.00 cash consideration, plus one contingent value right per underlying share.
Avadel Pharmaceuticals director Mark Anthony McCamish reported the automatic disposition of his holdings in connection with the acquisition of Avadel by Alkermes plc under a court-approved scheme of arrangement. His ordinary shares, including those held through a McCamish Charitable Remainder Trust, were converted and no shares remained beneficially owned after the transactions.
At the effective time of the deal on February 12, 2026, each outstanding Avadel ordinary share was exchanged for $21.00 in cash plus a non-transferable contingent value right for a potential additional $1.50 per share, dependent on specified milestones. His outstanding stock options were canceled and exchanged for cash based on the spread between the $21.00 cash consideration and the option exercise prices, and for one contingent value right for each underlying share.
Avadel Pharmaceuticals director Geoffrey Michael Glass reported disposing of his ordinary shares and stock options in connection with Alkermes plc’s acquisition of Avadel. The filing shows that, after these transactions on February 12, 2026, he no longer beneficially owns Avadel securities, whether directly or through trusts.
Under the Transaction Agreement and Irish scheme of arrangement, each outstanding Avadel ordinary share was converted into $21.00 in cash plus a non-transferable contingent value right for a potential additional $1.50 per share, subject to milestone achievement. All outstanding stock options held through trusts were canceled at the effective time and exchanged for cash based on the excess of the $21.00 cash consideration over the option exercise price, plus one CVR for each underlying share.
Avadel Pharmaceuticals director Eric J. Ende reported the cash-out of his equity in connection with the company’s acquisition by Alkermes plc. On February 12, 2026, his 219,905 Ordinary Shares were converted into $21.00 in cash per share plus a non-transferable contingent value right that may pay an additional $1.50 per share if specified milestones are achieved.
On the same date, multiple stock options to buy Ordinary Shares at exercise prices ranging from $1.49 to $16.32, with expirations from 2029 to 2035, were canceled. Each option grant was exchanged for cash based on the spread between the $21.00 cash consideration and the option’s exercise price, plus one contingent value right per underlying share. Following these transactions, Ende reported zero Ordinary Shares and options beneficially owned.
Avadel Pharmaceuticals Chief Executive Officer and director Gregory J. Divis Jr. reported the disposition of all his holdings in connection with the acquisition of Avadel by Alkermes plc. On February 12, 2026, each outstanding Avadel ordinary share was converted into $21.00 in cash plus a non‑transferable contingent value right that may pay an additional $1.50 per share if specified milestones are met.
Divis disposed of 211,105 ordinary shares held directly and 10,000 shares held through the Gregory J. Divis Jr. Revocable Trust. Multiple stock option awards with exercise prices ranging from $1.71 to $13.57, covering various numbers of ordinary shares, were canceled and exchanged for cash equal to their in‑the‑money value plus one contingent value right for each underlying share. After these transactions, the filing shows no ordinary shares or options beneficially owned.
Avadel Pharmaceuticals director Amin Naseem reported dispositions of all Avadel holdings in connection with the company’s acquisition by Alkermes. On February 12, 2026, 22,000 Ordinary Shares were converted into $21.00 in cash per share plus a potential $1.50 per-share contingent value right.
The filing also shows cancellation of stock options covering 49,500, 11,000 and 11,000 Ordinary Shares. Each option was exchanged for cash based on the spread over the $21.00 cash consideration and one contingent value right per underlying share.
Avadel Pharmaceuticals plc filed post-effective amendments to several prior shelf registration statements on Form S-3 and Form F-3 to deregister all securities that remained unsold. This step follows the completion of its acquisition by Alkermes plc under a court-sanctioned Irish scheme of arrangement.
As a result of the scheme, Avadel became a wholly owned subsidiary of Alkermes and terminated all public offerings under these registrations. The amendments formally remove any remaining unsold Avadel securities from registration and terminate the effectiveness of the affected registration statements.